Prio Wealth Limited Partnership raised its stake in Danaher Co. (NYSE:DHR – Free Report) by 0.6% during the third quarter, Holdings Channel reports. The firm owned 49,849 shares of the conglomerate’s stock after purchasing an additional 294 shares during the period. Prio Wealth Limited Partnership’s holdings in Danaher were worth $13,859,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Danaher by 7.4% in the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Danaher by 2.4% in the 2nd quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock valued at $1,490,112,000 after acquiring an additional 139,989 shares during the period. Capital Research Global Investors raised its stake in shares of Danaher by 1.0% in the 1st quarter. Capital Research Global Investors now owns 5,125,470 shares of the conglomerate’s stock valued at $1,279,932,000 after acquiring an additional 52,679 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Danaher by 2.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,398,649 shares of the conglomerate’s stock valued at $849,195,000 after acquiring an additional 85,081 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Danaher by 22.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after acquiring an additional 563,546 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.
Danaher Stock Down 1.0 %
DHR stock traded down $2.86 during mid-day trading on Monday, hitting $271.52. 445,846 shares of the company were exchanged, compared to its average volume of 2,706,759. The company has a market capitalization of $201.11 billion, a PE ratio of 46.51, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The firm has a fifty day simple moving average of $270.72 and a 200 day simple moving average of $260.13.
Danaher Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on DHR. The Goldman Sachs Group raised their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Wells Fargo & Company began coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price on the stock. Stephens began coverage on shares of Danaher in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 target price on the stock. Robert W. Baird raised their target price on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price target on shares of Danaher in a research note on Friday, September 6th. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $282.12.
Get Our Latest Stock Analysis on Danaher
Insider Activity
In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 39,659 shares of company stock valued at $11,042,433. Company insiders own 11.10% of the company’s stock.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
- Five stocks we like better than Danaher
- How to Invest in Insurance Companies: A GuideĀ
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- What is a Secondary Public Offering? What Investors Need to Know
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.